BR0208809A - Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo - Google Patents

Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo

Info

Publication number
BR0208809A
BR0208809A BR0208809-6A BR0208809A BR0208809A BR 0208809 A BR0208809 A BR 0208809A BR 0208809 A BR0208809 A BR 0208809A BR 0208809 A BR0208809 A BR 0208809A
Authority
BR
Brazil
Prior art keywords
antibody
autoimmune diseases
kit
osteopontin
therapeutic agent
Prior art date
Application number
BR0208809-6A
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Yukihiko Saeki
Yasuyuki Yokosaki
Masaki Noda
Nobuchika Yamamoto
Original Assignee
Immuno Biolog Labiratories Co
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biolog Labiratories Co, Fujisawa Pharmaceutical Co filed Critical Immuno Biolog Labiratories Co
Publication of BR0208809A publication Critical patent/BR0208809A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANTICORPO DE ANTI-OSTEOPONTINA, AGENTE TERAPêUTICO PARA TRATAR DOENçAS AUTOIMUNES, MéTODO E KIT DE DETECçãO DE ANORMALIDADES INFLAMATóRIAS E USO DO ANTICORPO". Anticorpo anti-asteopontina que inibe a ligação de integrina reconhecendo a seq³ência RGD à osteopontina ou seu fragmento, e que inibe a ligação de uma integrina reconhecendo a seq³ência SVVYGLR ou seq³ência equivalente à mesma, à osteopontina ou a seu fragmento. Este anticorpo é útil em medicamentos para doenças autoimunes, para reumatismo e para artrite reumatóide. é também provido em método pata tratar doenças autoimunes, reumatismo e artrite reumatóide. Este anticorpo também é útil no diagnóstico e método diagnóstico para reumatismo.
BR0208809-6A 2001-04-05 2002-04-04 Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo BR0208809A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001107578 2001-04-05
JP2001290700 2001-09-25
PCT/JP2002/003382 WO2002081522A1 (fr) 2001-04-05 2002-04-04 Anticorps dirigé contre l'ostéopontine, et son utilisation

Publications (1)

Publication Number Publication Date
BR0208809A true BR0208809A (pt) 2004-03-09

Family

ID=26613159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208809-6A BR0208809A (pt) 2001-04-05 2002-04-04 Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo

Country Status (20)

Country Link
US (2) US20040234524A1 (pt)
EP (2) EP1754719A3 (pt)
JP (1) JP4230776B2 (pt)
KR (1) KR100881900B1 (pt)
CN (1) CN100469793C (pt)
AR (1) AR033121A1 (pt)
AT (1) ATE412013T1 (pt)
AU (1) AU2002244968B2 (pt)
BR (1) BR0208809A (pt)
CA (1) CA2443330A1 (pt)
CZ (1) CZ20032697A3 (pt)
DE (1) DE60229509D1 (pt)
ES (1) ES2314040T3 (pt)
HU (1) HUP0401561A2 (pt)
MX (1) MXPA03009052A (pt)
NO (1) NO20034405L (pt)
NZ (1) NZ528483A (pt)
PL (1) PL366469A1 (pt)
RU (1) RU2299888C2 (pt)
WO (1) WO2002081522A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532633A (ja) * 2001-05-09 2004-10-28 ビオ・ビジョン・アーゲー 進行性の慢性痴呆疾患の検出方法、これに適したペプチド及び検出試薬
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP1431310A4 (en) * 2001-09-25 2005-03-23 Immuno Biological Lab Co Ltd ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004103403A1 (ja) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. 免疫担当細胞活性化阻害剤およびその用途
WO2005020785A2 (en) * 2003-07-15 2005-03-10 The Regents Of The University Of California Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
AU2004324192A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
JP4871740B2 (ja) 2005-01-13 2012-02-08 株式会社ジーンテクノサイエンス 抗α９インテグリン抗体とその用途
CA2653661A1 (en) * 2006-05-31 2007-12-06 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
WO2007149948A2 (en) * 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
KR101429783B1 (ko) 2006-07-12 2014-08-18 가부시키가이샤 진 테크노 사이언스 항 인간 α９ 인테그린 항체와 그 용도
EP2077325A4 (en) * 2006-09-11 2012-04-11 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
DK2075258T3 (da) 2006-10-26 2012-09-17 Gene Techno Science Co Ltd Antistof mod RGD i en aminosyresekvens i et ekstracellulært matrixprotein samt fremgangsmåde til dets fremstilling og dets anvendelse
CN101293916A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
EP2201383B1 (en) 2007-10-10 2014-01-15 Roche Diagnostics GmbH Means and methods for monitoring myocardial infarction and its treatment
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
JP2011509650A (ja) 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
CN101918549B (zh) 2008-01-11 2012-11-28 财团法人化学及血清疗法研究所 改良的人源化的抗-人α9-整联蛋白抗体
CA2721716C (en) 2008-04-24 2019-09-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
EP2399937B1 (en) 2009-02-23 2016-04-27 Gene Techno Science Co., Ltd. Anti-human alpha9 integrin antibody and use thereof
EP2406285B1 (en) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
EP2431738A4 (en) * 2009-05-12 2013-05-22 Innopharmascreen Inc SCREENING PROCESS FOR OSTEOPONTIN INHIBITOR AND INHIBITOR MANUFACTURED THEREWITH
US8617829B2 (en) 2009-09-24 2013-12-31 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
WO2012117067A1 (en) 2011-03-01 2012-09-07 Novo Nordisk A/S Antagonistic dr3 ligands
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2021030209A1 (en) * 2019-08-09 2021-02-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic antibodies against osteopontin
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63241A (en) * 1867-03-26 Jacob green
US63247A (en) * 1867-03-26 hbtdeick
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US705842A (en) * 1901-10-25 1902-07-29 Daniel M Moroney Machine for assembling links in making chain belts.
US5459060A (en) * 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
EP0705842A2 (en) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
US6414219B1 (en) * 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
CA2370301A1 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Osteopontin-derived chemotactic and inhibitory agents and uses therefor
DE60131525T2 (de) * 2000-03-23 2008-09-25 Glaxo Group Ltd., Greenford Verfahren zum screening von inhibitoren für osteopontin
EP1431310A4 (en) * 2001-09-25 2005-03-23 Immuno Biological Lab Co Ltd ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF

Also Published As

Publication number Publication date
EP1375518A4 (en) 2004-12-08
AR033121A1 (es) 2003-12-03
AU2002244968B2 (en) 2007-07-26
JP4230776B2 (ja) 2009-02-25
DE60229509D1 (de) 2008-12-04
RU2299888C2 (ru) 2007-05-27
CA2443330A1 (en) 2002-10-17
NO20034405D0 (no) 2003-10-02
HUP0401561A2 (hu) 2004-11-29
EP1754719A3 (en) 2007-05-16
CN1513000A (zh) 2004-07-14
NZ528483A (en) 2008-03-28
EP1375518B1 (en) 2008-10-22
PL366469A1 (en) 2005-02-07
MXPA03009052A (es) 2004-10-15
EP1375518A1 (en) 2004-01-02
US20080069815A1 (en) 2008-03-20
US20040234524A1 (en) 2004-11-25
JPWO2002081522A1 (ja) 2004-07-29
CZ20032697A3 (cs) 2004-01-14
CN100469793C (zh) 2009-03-18
ATE412013T1 (de) 2008-11-15
KR100881900B1 (ko) 2009-02-04
WO2002081522A1 (fr) 2002-10-17
RU2003132446A (ru) 2005-04-27
ES2314040T3 (es) 2009-03-16
NO20034405L (no) 2003-12-05
EP1754719A2 (en) 2007-02-21
KR20030092022A (ko) 2003-12-03

Similar Documents

Publication Publication Date Title
BR0208809A (pt) Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
Lee et al. Effect of extracorporeal shockwave therapy versus intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
BRPI0408063A (pt) métodos e composições envolvendo mda-7
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
BRPI0604739A (pt) sistema de terapia de ultra-som com agente de contraste aumentado com guia de imagem de ultra-som para tratamento de trombo
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
ATE506959T1 (de) Verwendung von il-18 inhibitoren
BR9914735A (pt) Processo para tratamento de sépsia
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
BRPI0417105A (pt) métodos de tratamento de doenças autoimunológicas em pacientes
BRPI0417146A (pt) combinações farmacêuticas
BR112022003918A2 (pt) Rebamipida para uso na prevenção e tratamento da doença de crohn
CY1116995T1 (el) Ναταλιζουμαμπη για χρηση στην θεραπεια ασθενειων που απαιτουν θεραπεια στεροειδους
FR2846658B1 (fr) Peptides pour la prevention, le diagnostic et le traitement de la leptospirose animale et/ou humaine.
Kim et al. Acute calcific tendinitis of the flexor digitorum superficialis of the finger: a case report
Baker Advances in Medical Therapeutics
BRPI0407333A (pt) Uso de antagonistas do receptor b2 de bradiquinina para o tratamento de osteoartrose
BR112015022967A8 (pt) anticorpos anti-gd2 de alta afinidade.
Parker Drug Addicts-Sentence-An American Viewpoint

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IMMUNO-BIOLOGICAL LABIRATORIES CO., LTD.. (JP) , Y

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: IMMUNO-BIOLOGICAL LABIRATORIES CO., LTD.. (JP) , A

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.